• Luz Ángela Castro, María Inés Álvarez, Florencia Rojas, Gustavo Giusiano, and Ernesto Martínez.
• Universidad del Valle, Facultad de Salud, Escuela de Bacteriología y Laboratorio Clínico, Cali, Colombia.
• Colomb Medica. 2019 Dec 30; 50 (4): 293-298.

BackgroundCandida auris is an emerging yeast frequently reported as resistant to multiple antifungal drugs commonly used to treat Candida infections. This specie can colonize the patient's skin and has great ability for producing outbreaks in hospitals. C. auris is phylogenetically related to other Candida species, can be misidentified using conventional biochemical or commercial methods and requires specific technology for its identification.Case ReportWe report the first isolate of C. auris in Cali, Colombia, from a central venous catheter in a 37-year-old patient with rheumatoid arthritis and endocarditis who did not have symptoms of sepsis. The yeast was initially misidentified as C. haemulonii using the Phoenix system and subsequently identified as C. auris by matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS). The broth microdilution method was used to determine the minimum inhibitory concentration; the isolate was susceptible to fluconazole, itraconazole, voriconazole and amphotericin B.ConclusionsThis report contributes to knowledge of the epidemiology of C. auris infections in individuals with underlying disease and describes an isolate with a behavior different from what is usually reported.Copyright © 2019 Universidad del Valle.

31 keywords...

hide…